Edition:
United Kingdom

Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D


Monday, 26 Feb 2018 

Feb 26 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D.CATALYST BIOSCIENCES INC - PLAN TO INITIATE A PHASE 2B STUDY OF CB 2679D IN INDIVIDUALS WITH SEVERE HEMOPHILIA B IN Q3 OF 2018. 

Company Quote

8.28
 --
20 May 2019